ARTIMPLANT YEAR-END REPORT JANUARY - DECEMBER 2007

ARTIMPLANT YEAR-END REPORT JANUARY - DECEMBER 2007

Västra Frölunda, Sweden, February 22, 2008, 08:45 CET (GMT+1)

• Net revenue for the fourth quarter increased to SEK 5.0 million (1.6) and for
the year to SEK 16.3 million (5.5)*
• The net loss for the fourth quarter improved to SEK -2.1 million (-9.5) and
for the year to SEK 13.4 million (-56.0)
• The net loss for the year, excluding non-recurring items, improved to SEK 11.8
million (-38.9)
• Earnings per share for the year improved to SEK -0.23 (-0.95)
• Sales of Artelon® CMC Spacer amounted to approximately 3,900 (2,750) units, of
which approximately 1,100 (1,050) were during the fourth quarter
• Over 6,000 patients were treated with Artelon® implants up to and including
2007
• Artelon® Tissue Reinforcement was granted FDA clearance for several new
indications
• FDA clearance for two new Spacer products
• An agreement was signed with Small Bone Innovations for new resurfacing
indications for the hand and wrist

Artimplant will hold a telephone conference on this report on February 22, 2008
at 11am, Central European Time (GMT+1). For further information see
www.artimplant.com.

* Figures in brackets refer to the corresponding period last year

For further information, please contact:
Hans Rosén, CEO, phone +46 (0)31-746 56 00, +46 (0)708 58 34 70,
hans.rosen@artimplant.com

Lars-Johan Cederbrant, CFO, phone +46 (0)31-746 56 54, +46 (0)703 01 68 54,
lars-johan.cederbrant@artimplant.com

Further information at www.artimplant.com where one also can subscribe to future
press releases;
www.artimplant.com/investors-media/subscribe-to-press-releases.html

About Artimplant
Artimplant is a biomaterials company focused on solutions to problems in
orthopedic and oral surgery. We restore health through the development,
production, and marketing of degradable implants that regenerate body functions
and improve quality of life. Our products, made from Artelon®, meet unmet
clinical needs and are marketed in a growing number of therapy areas. Artimplant
produces implants for treatment of osteoarthritis in hands and feet, for
shoulder and other soft tissue injuries as well as oral applications.

Artimplant is a public company listed on the OMX Nordic Exchange Stockholm in
the Small Cap segment and in the healthcare sector.

Forward-looking statements
This press release contains forward-looking statements as defined in the U.S.
Private Securities Litigation Reform Act of 1995. Readers are cautioned not to
place undue reliance on these forward-looking statements. Actual results may
differ materially from those indicated by these forward-looking statements as a
result of risks and uncertainties impacting the Company's business including
increased competition; the ability of the Company to expand its operations and
to attract and retain qualified professionals; technological obsolescence;
general economic conditions; and other risks detailed from time to time in the
Company's filings.